摘要
目的通过对某三甲肿瘤专科医院乳腺癌化疗费用的比较分析,对改进完善现行医疗保险制度提出意见建议。方法选取2014年1227例乳腺癌诊疗费用,分别按照不同的基础药物、病程、基因突变类型以及年龄段进行分类,对各项诊疗费用进行单项和综合比较。结果经比较分析,紫杉类为基础的化疗方案次均总费用为12558.52元,远高于蒽环类化疗方案的5986.85元;晚期方案的次均总费用14134.13,在不同病程对应的方案中最高,且其中自费药品占比最高,占49%;其他数据比较无明显差异。结果影响乳腺癌化疗诊疗费用的因素主要包括药品纳入医保报销目录的情况以及自费药品使用情况。应加强乳腺癌早期筛查,规范优化乳腺癌诊疗,适当扩大医保适应症范围和医保药品目录。
Objective to improve and perfect the existing medical insurance system by comparing and analyzing the cost of chemotherapy for breast cancer in a hospital. Methods 1227 cases of breast cancer diagnosis and treatment costs in 2014 were classified according to different basic medicine, course of disease, gene mutation and age. The results of the comparative analysis of taxane based chemotherapy costs are generally much higher type than those of anthracycline chemotherapy; advanced programs are the highest total costs, and the expense of drugs accounted for the highest; other data had no significant difference or no reference value. And then analyze the factors that affect the cost of chemotherapy and treatment of breast cancer include： the use of drugs into the Medicare reimbursement list and the use of drugs at their own expense. Conclusion to strengthen the early screening of breast cancer, standardize and optimize the diagnosis and treatment of breast cancer, expand the scope of medical insurance and medical insurance.
出处
《中国病案》
2017年第2期69-72,共4页
Chinese Medical Record
关键词
乳腺癌
化疗
医保费用
分析
Breast cancer
chemotherapy
Medical insurance cost
analysis
